Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4,077 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Multi-laboratory evaluation of immunoaffinity LC-MS-based glucagon-like peptide-1 assay.
Ishikawa R, Saito K, Tachiki H, Goda R, Arai K, Shimizu H, Andou T, Takahara K, Uchiyama H, Nitta SI, Kakehi M, Hayashi K, Katagiri N, Kojima K, Fujita H, Tsuchinaga K, Saito Y. Ishikawa R, et al. Among authors: fujita h. Bioanalysis. 2023 Feb;15(4):207-218. doi: 10.4155/bio-2022-0240. Epub 2023 Mar 24. Bioanalysis. 2023. PMID: 36961372
Interlaboratory evaluation of LC-MS-based biomarker assays.
Saito K, Goda R, Arai K, Asahina K, Kawabata M, Uchiyama H, Andou T, Shimizu H, Takahara K, Kakehi M, Yamauchi S, Nitta SI, Suga T, Fujita H, Ishikawa R, Saito Y. Saito K, et al. Among authors: fujita h. Bioanalysis. 2024 Mar;16(6):389-402. doi: 10.4155/bio-2023-0173. Epub 2024 Feb 9. Bioanalysis. 2024. PMID: 38334082 Review.
Potent Body Weight-Lowering Effect of a Neuromedin U Receptor 2-selective PEGylated Peptide.
Kanematsu-Yamaki Y, Nishizawa N, Kaisho T, Nagai H, Mochida T, Asakawa T, Inooka H, Dote K, Fujita H, Matsumiya K, Hirabayashi H, Sakamoto J, Ohtaki T, Takekawa S, Asami T. Kanematsu-Yamaki Y, et al. Among authors: fujita h. J Med Chem. 2017 Jul 27;60(14):6089-6097. doi: 10.1021/acs.jmedchem.7b00330. Epub 2017 Jul 18. J Med Chem. 2017. PMID: 28657315
Differential effects of selective agonists of neuromedin U1 and U2 receptors in obese and diabetic mice.
Nagai H, Kaisho T, Yokoyama K, Asakawa T, Fujita H, Matsumiya K, Noguchi J, Tsuchimori K, Nishizawa N, Kanematsu-Yamaki Y, Dote K, Inooka H, Sakamoto JI, Ohtaki T, Asami T, Takekawa S. Nagai H, et al. Among authors: fujita h. Br J Pharmacol. 2018 Jan;175(2):359-373. doi: 10.1111/bph.14077. Epub 2017 Dec 18. Br J Pharmacol. 2018. PMID: 29057457 Free PMC article.
Discovery of 5-Chloro-1-(5-chloro-2-(methylsulfonyl)benzyl)-2-imino-1,2-dihydropyridine-3-carboxamide (TAK-259) as a Novel, Selective, and Orally Active α1D Adrenoceptor Antagonist with Antiurinary Frequency Effects: Reducing Human Ether-a-go-go-Related Gene (hERG) Liabilities.
Sakauchi N, Kohara Y, Sato A, Suzaki T, Imai Y, Okabe Y, Imai S, Saikawa R, Nagabukuro H, Kuno H, Fujita H, Kamo I, Yoshida M. Sakauchi N, et al. Among authors: fujita h. J Med Chem. 2016 Apr 14;59(7):2989-3002. doi: 10.1021/acs.jmedchem.5b01528. Epub 2016 Mar 17. J Med Chem. 2016. PMID: 26954848
Antiobesity and emetic effects of a short-length peptide YY analog and its PEGylated and alkylated derivatives.
Niida A, Kanematsu-Yamaki Y, Asakawa T, Ishimura Y, Fujita H, Matsumiya K, Nishizawa N, Adachi Y, Mochida T, Tsuchimori K, Yoneyama-Hirozane M, Sakamoto J, Hirabayashi H, Fukui H, Takekawa S, Asami T. Niida A, et al. Among authors: fujita h. Bioorg Med Chem. 2018 Feb 1;26(3):566-572. doi: 10.1016/j.bmc.2017.12.014. Epub 2017 Dec 8. Bioorg Med Chem. 2018. PMID: 29279243
Discovery of novel and potent orally active calcium-sensing receptor antagonists that stimulate pulselike parathyroid hormone secretion: synthesis and structure-activity relationships of tetrahydropyrazolopyrimidine derivatives.
Yoshida M, Mori A, Kotani E, Oka M, Makino H, Fujita H, Ban J, Ikeda Y, Kawamoto T, Goto M, Kimura H, Baba A, Yasuma T. Yoshida M, et al. Among authors: fujita h. J Med Chem. 2011 Mar 10;54(5):1430-40. doi: 10.1021/jm101452x. Epub 2011 Feb 9. J Med Chem. 2011. PMID: 21306167
Novel and potent calcium-sensing receptor antagonists: discovery of (5R)-N-[1-ethyl-1-(4-ethylphenyl)propyl]-2,7,7-trimethyl-5-phenyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide monotosylate (TAK-075) as an orally active bone anabolic agent.
Yoshida M, Mori A, Morimoto S, Kotani E, Oka M, Notoya K, Makino H, Ono M, Shirasaki M, Tada N, Fujita H, Ban J, Ikeda Y, Kawamoto T, Goto M, Kimura H, Baba A, Yasuma T. Yoshida M, et al. Among authors: fujita h. Bioorg Med Chem. 2011 Mar 15;19(6):1881-94. doi: 10.1016/j.bmc.2011.02.001. Epub 2011 Feb 24. Bioorg Med Chem. 2011. PMID: 21353570
4,077 results